Author

Cristina Suárez Ferrer

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN_S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN_S DISEASE

UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE
UTILITY OF USTEKINUMAB IN ARTICULAR PATHOLOGY ASSOCIATED WITH CROHN´S DISEASE

Cristina Suárez Ferrer  et al.

ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE
ANTI-TNF SERUM CONCENTRATIONS ARE ASSOCIATED WITH ENDOSCOPIC REMISSION IN CROHN´S DISEASE

Cristina Suárez Ferrer  et al.

CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS
CLINICAL CHARACTERISTICS AND PROGNOSIS OF COVID-19 IN A SPANISH COHORT OF INFLAMMATORY BOWEL DISEASE PATIENTS

Cristina Suárez Ferrer  et al.

ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE
ADALIMUMAB TROUGH LEVELS ARE ASSOCIATED WITH CLINICAL, BIOLOGICAL AND ENDOSCOPIC REMISSION IN PATIENTS WITH CROHN´S DISEASE

Cristina Suárez Ferrer  et al.

COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
COMPARISON OF SERUM ADALIMUMAB TROUGH LEVELS IN 40MG WEEKLY VS 80MG EVERY TWO WEEKS INTENSIFICATION REGIMES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Cristina Suárez Ferrer  et al.

INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY
INCIDENCE AND RISK FACTORS ASSOCIATED WITH RECURRENCE OF CROHN´S DISEASE AFTER DEFINITIVE PANPROCTOCOLECTOMY AND ILEOSTOMY: THE IFARPI STUDY

Cristina Suárez Ferrer  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES' OUTCOMES (DUMBO REGISTRY)

Cristina Suárez Ferrer  et al.

IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU
IMPACT OF BIOLOGICAL AGENTS ON POSTOPERATIVE COMPLICATIONS IN INFLAMMATORY BOWEL DISEASE: A MULTICENTRE STUDY OF GETECCU

Cristina Suárez Ferrer  et al.

SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION
SERUM PREVALENCE OF SARS-COV2 ANTIBODIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE BEFORE VACCINATION

Cristina Suárez Ferrer  et al.

ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE
ADALIMUMAB TROUGH LEVELS DURING INDUCTION ARE NOT ASSOCIATED WITH BIOCHEMICAL REMISSION IN PATIENTS WITH CROHN’S DISEASE

Cristina Suárez Ferrer  et al.

INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE
INTESTINAL ULTRASOUND FEATURES ASSOCIATED WITH RESPONSE TO ADALIMUMAB IN PATIENTS WITH CROHN’S DISEASE

Cristina Suárez Ferrer  et al.

SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)
SAFETY OF INFLAMMATORY BOWEL DISEASE DRUGS DURING PREGNANCY AND BREASTFEEDING: MOTHERS AND BABIES’ OUTCOMES (DUMBO REGISTRY)

Cristina Suárez Ferrer  et al.

Item 1 - 13 / 13
1